View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. News
July 1, 2022

Twist and Ildong to develop antibodies for immuno-oncology applications

Under the deal, Twist will receive upfront, milestone and royalty payments as well as annual maintenance fees.

Ildong Pharmaceutical will licence a suite of Twist Bioscience’s VHH antibody libraries after the two companies entered a partnership agreement.

Twist’s VHH libraries, used for discovering and developing antibodies for use in immuno-oncology, will be licensed by Ildong for three years for research and development works. 

Twist will be entitled to receive an upfront payment, annual maintenance fees, further payments on successfully meeting clinical and regulatory milestones and royalty payments on product sales.

Twist Bioscience CEO and co-founder Emily Leproust said: “We believe our VHH libraries are extremely versatile in their applications developing novel and next-generation therapies. 

“Because they are significantly smaller than a traditional human antibody, they can be combined with other technologies, or used on their own for development of effective therapies. 

“This VHH library licensing agreement with Ildong is our first collaboration with a South Korea-based company and broadens our presence in the Asia-Pacific region.”

Antibodies comprise two variable domains, heavy and light chains. 

A VHH antibody or a single domain antibody is the antigen-attaching domain of the heavy chain and has three complementary determining regions (CDRs) or regions where antigens attach to the antibody. 

The VHH libraries of Twist leverage new methods that merge synthetic and natural methods to enhance diversity in the ten billion antibody library, offering improved quality VHH libraries for usage against any protein target. 

VHH antibodies’ small size permits them to reach targets that conventional antibodies cannot with strongly attaching affinity. 

The modular nature of such antibodies aid in the development of bi- or multi-specific antibodies suitable for creating new therapies for oncology, autoimmune disease and virology areas.

In May this year, the company signed a research partnership and exclusive option licence deal with Astellas Pharma for developing antibodies to lower tumour microenvironment-mediated immunosuppression.

Related Companies

Topics in this article:
NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. A weekly roundup of the latest news and analysis, sent every Friday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy


Thank you for subscribing to Pharmaceutical Technology